Company intelligence / Profile preview

BreathDX

England, United Kingdom

Ownership: Private
Development stage: Other

Overview

BreathDX has developed the AmBeR device, a breath analysis platform aimed at non-invasive, rapid measurement of ammonia in breath for disease diagnosis and management. The platform has demonstrated potential in distinguishing metabolic and infectious diseases (such as ventilator-associated pneumonia) and is progressing toward clinical adoption in the UK and internationally, backed by device-to-market government funding.

Therapeutic areas: GastroenterologyInfectious DiseasesOtherRare Diseases
Modalities: DeviceNanotechnology
Industry: Metabolite Diagnostics

Partnerships

Dublin City University (technology licensing, equity stakeholder)UK government (funding support)

Beyond the preview

Go deeper on BreathDX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BreathDX.

Explore the full profile